FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns chemical pharmaceutical industry, particularly a combination including selective cyclooxygenase-2 (COX-2) inhibitor and epothilone. COX-2 inhibitor can be 5-methyl-2-(2'-chlor-6'-fluoranilino)phenylacetic acid or its pharmaceutically acceptable salt. The combination can be applied in treatment of precancerous colon lesions or colon cancer as well as other malignant diseases. The invention also claims consumer package including cyclooxygenase-2 inhibitor and epothilone with manual for simultaneous, separate or alternating application of the medications for proliferative disease treatment.
EFFECT: reduction of side effects during epothilone treatment.
12 cl, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF CYCLOOXYGENASE 2 INHIBITOR AND HISTONE DEACETYLASE INHIBITOR | 2002 |
|
RU2311200C2 |
| APPLICATION OF PYRAZOLINE DERIVATIVES TO PRODUCE PHARMACEUTICAL FOR PREVENTION AND/OR TREATMENT OF DISEASES ASSOCIATED WITH CELL PROLIFERATION | 2002 |
|
RU2305545C2 |
| PHARMACEUTICAL COMPOSITION FOR USING IN THERAPY OF MALIGNANT NEOPLASM COMPRISING COMBINATION OF BISPHOSPHONATE, COX-2 INHIBITOR AND TAXOL | 2002 |
|
RU2317819C2 |
| MDM2 INHIBITORS AND COMBINATIONS THEREOF | 2016 |
|
RU2740091C2 |
| COMBINATIONS INCLUDING EPOTHILONES, AND THEIR PHARMACEUTICAL APPLICATION | 2002 |
|
RU2375058C2 |
| SPECIFIC 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES | 1998 |
|
RU2186762C2 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| PREPARATION FOR TREATING AND PREVENTING CACHEXIA | 1998 |
|
RU2190399C2 |
| COMBINED THERAPY | 2015 |
|
RU2695230C2 |
| COMBINATIONS CONTAINING ANTIDIARRHEAL AGENT AND EPOTHYLON OR EPOTHYLON DERIVATIVES | 2002 |
|
RU2330661C2 |
